About Mirror Biologics
Mirror Biologics is a company based in Tampa (United States) founded in 2018 by Michael Har-Noy.. Mirror Biologics has raised $30 million across 2 funding rounds from investors including BRADBURY. Mirror Biologics offers products and services including AlloStim and Mirror Effect Technology. Mirror Biologics operates in a competitive market with competitors including ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and OncoResponse, among others.
- Headquarter Tampa, United States
- Founders Michael Har-Noy
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Mirror Biologics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$30 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Series A
Oct 11, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mirror Biologics
Mirror Biologics offers a comprehensive portfolio of products and services, including AlloStim and Mirror Effect Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutic cells that modulate immune responses for cancer and diseases.
Enables development of immunomodulatory treatments for various medical needs.
Unlock access to complete
Unlock access to complete
Funding Insights of Mirror Biologics
Mirror Biologics has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $20 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $20.0M
-
First Round
First Round
(09 Dec 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2022 | Amount | Series A - Mirror Biologics | Valuation | BRADBURY |
|
| Dec, 2021 | Amount | Series A - Mirror Biologics | Valuation | BRADBURY |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mirror Biologics
Mirror Biologics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BRADBURY. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
It serves as a bradbury.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mirror Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mirror Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mirror Biologics Comparisons
Competitors of Mirror Biologics
Mirror Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and OncoResponse, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapies for cancer treatment are developed via proprietary antibody platform.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mirror Biologics
Frequently Asked Questions about Mirror Biologics
When was Mirror Biologics founded?
Mirror Biologics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is Mirror Biologics located?
Mirror Biologics is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Who is the current CEO of Mirror Biologics?
Michael Har-Noy is the current CEO of Mirror Biologics. They have also founded this company.
Is Mirror Biologics a funded company?
Mirror Biologics is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Dec 09, 2021.
What does Mirror Biologics do?
Developer of next-generation immunotherapy products. The lead product AlloStim is a bioengineered, non-genetically altered CD4 Th1-like memory cell with anti-CD3anti-CD28 coated microbead that has potent immunomodulatory properties and causes the down-regulation of checkpoint inhibitor molecules, such as PD-1L1 and CTLA4. Chaperone Rich Cell Lysate are heat shock proteins purified from a lysed tumor or virally infected cells which preserve the chaperoned peptides that contain tumor neoantigens. The company also developed immunomodulatory vaccines that affect the immune system and provides immune counter-measures to prevent tumors and infected cells.
Who are the top competitors of Mirror Biologics?
Mirror Biologics's top competitors include Alector, Hummingbird Bioscience and Alpine Immune Sciences.
What products or services does Mirror Biologics offer?
Mirror Biologics offers AlloStim and Mirror Effect Technology.
Who are Mirror Biologics's investors?
Mirror Biologics has 1 investor. Key investors include BRADBURY.